96. Jahrestagung der Deutschen Gesellschaft für Pathologie e. V ...

Abstracts
FR-035
MAP3K7 deletions have prognostic relevance in prostate cancer
M . Kluth 1 , A . Krohn 1 , J . Hesse 1 , R . Simon 1 , T . Schlomm 2 , H . Huland 2 , G . Sauter 1 ,
S . Minner 1
1 University Medical Center Hamburg-Eppendorf, Hamburg, 2 Martini-Clinic,
Hamburg
Aims. MAP3K7 (mitogen-activated protein kinase kinase kinase 7) gene
is a component of the MAPK-pathway and plays a central role in cell
growth, differentiation and apoptosis. The MAP3K7 gene is located at
6q15, a region, which is commonly deleted in prostate cancer. The aim
of this study was to examine the potential relevance of MAP3K7 (6q15)
deletions in prostate cancer with respect to tumor phenotype and clinical
outcome.
Methods. A prostate tissue microarray (TMA) with clinical follow-up
data consisting of over 4500 prostate cancer samples was analyzed for
MAP3K7 deletions by fluorescence in situ hybridization (FISH). Results
were correlated with tumor phenotype, clinical outcome and ERG
expression. In addition, 15 tumors with known MAP3K7 deletion and
14 tumors without MAP3K7 deletions were examined for the presence of
MAP3K7 mutations (Exon 1–17).
Results. Heterozygous MAP3K7 deletions were found in 18.5% (423/2289)
of all analyzable prostate cancers. MAP3K7 deletions were associated
with advanced tumor stage (p